Skip to main content

Zynteglo Disease Interactions

There are 3 disease interactions with Zynteglo (betibeglogene autotemcel).

Moderate

Betibeglogene (applies to Zynteglo) HIV

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: HIV Infection

Betibeglogene has not been studied in patients with HIV. A negative serology test for HIV is necessary before the collection of cells, to ensure acceptance of apheresis material for betibeglogene manufacturing. Material from patients with a positive HIV test, will not be accepted for manufacturing.

References

  1. (2022) "Product Information. Zynteglo (betibeglogene autotemcel)." bluebird bio
Moderate

Betibeglogene (applies to Zynteglo) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Betibeglogene has not been studied in patients with hepatic impairment. Patients should be assessed for hepatic impairment to ensure that hematopoietic stem cell (HSC) transplantation is appropriate. Additionally, screening for hepatitis B and C should be performed before cell collection, to ensure acceptance of apheresis material for betibeglogene manufacturing.

References

  1. (2022) "Product Information. Zynteglo (betibeglogene autotemcel)." bluebird bio
Moderate

Betibeglogene (applies to Zynteglo) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Betibeglogene has not been studied in patients with renal impairment. Patients should be assessed for renal impairment, to ensure that hematopoietic stem cell (HSC) transplantation is appropriate.

References

  1. (2022) "Product Information. Zynteglo (betibeglogene autotemcel)." bluebird bio

Zynteglo drug interactions

There are 44 drug interactions with Zynteglo (betibeglogene autotemcel).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer